{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:54:43Z","timestamp":1790610883684,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H03092"],"award-info":[{"award-number":["21H03092"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00417-025-06930-6","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T08:35:52Z","timestamp":1754728552000},"page":"3073-3079","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["One-year outcomes of three-monthly and four-monthly loading regimens of faricimab for treatment-na\u00efve neovascular age-related macular degeneration"],"prefix":"10.1007","volume":"263","author":[{"given":"Yuta","family":"Doi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5248-5762","authenticated-orcid":false,"given":"Masayuki","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Ideyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Kido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Ueda-Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotaro","family":"Ooto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Tsujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"6930_CR1","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(08)61759-6","volume":"372","author":"HR Coleman","year":"2008","unstructured":"Coleman HR, Chan C-C, Ferris FL 3rd, Chew EY (2008) Age-related macular degeneration. Lancet 372:1835\u20131845","journal-title":"Lancet"},{"key":"6930_CR2","doi-asserted-by":"publisher","first-page":"100125","DOI":"10.1016\/j.xops.2022.100125","volume":"2","author":"A Kido","year":"2022","unstructured":"Kido A, Miyake M, Tamura H et al (2022) Incidence and clinical practice of exudative age-related macular degeneration: a nationwide population-based cohort study. Ophthalmol Sci 2:100125","journal-title":"Ophthalmol Sci"},{"key":"6930_CR3","doi-asserted-by":"publisher","first-page":"S112","DOI":"10.37765\/ajmc.2020.43436","volume":"26","author":"W Wong","year":"2020","unstructured":"Wong W (2020) Managed care opportunities and approaches to select treatment for sight preservation. Am J Manag Care 26:S112\u2013S117","journal-title":"Am J Manag Care"},{"key":"6930_CR4","first-page":"27","volume":"5","author":"WR Green","year":"1999","unstructured":"Green WR (1999) Histopathology of age-related macular degeneration. Mol Vis 5:27","journal-title":"Mol Vis"},{"key":"6930_CR5","doi-asserted-by":"publisher","first-page":"100954","DOI":"10.1016\/j.preteyeres.2021.100954","volume":"84","author":"A Uemura","year":"2021","unstructured":"Uemura A, Fruttiger M, D\u2019Amore PA et al (2021) VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog Retin Eye Res 84:100954","journal-title":"Prog Retin Eye Res"},{"key":"6930_CR6","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP et al (2021) Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye 35:1305\u20131316","journal-title":"Eye"},{"key":"6930_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y et al (2020) HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127:72\u201384","journal-title":"Ophthalmology"},{"key":"6930_CR8","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"ES Gragoudas","year":"2004","unstructured":"Gragoudas ES, Adamis AP, Cunningham ET Jr et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805\u20132816","journal-title":"N Engl J Med"},{"key":"6930_CR9","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"6930_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1167\/iovs.64.5.28","volume":"64","author":"D Sharma","year":"2023","unstructured":"Sharma D, Zachary I, Jia H (2023) Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseases. Invest Ophthalmol Vis Sci 64:28","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6930_CR11","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2147\/DDDT.S115121","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang S, Zhao J, Sun X (2016) Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther 10:1857\u20131867","journal-title":"Drug Des Devel Ther"},{"key":"6930_CR12","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, Lundh von Leithner P, Foxton R et al (2016) Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med 8:1265\u20131288","journal-title":"EMBO Mol Med"},{"key":"6930_CR13","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1517\/14712598.2016.1167182","volume":"16","author":"M Hassan","year":"2016","unstructured":"Hassan M, Afridi R, Sadiq MA et al (2016) The role of aflibercept in the management of age-related macular degeneration. Expert Opin Biol Ther 16:699\u2013709","journal-title":"Expert Opin Biol Ther"},{"key":"6930_CR14","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/s41433-024-03218-7","volume":"38","author":"C Goodchild","year":"2024","unstructured":"Goodchild C, Bailey C, Soto Hernaez J et al (2024) Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye 38:3059\u20133064","journal-title":"Eye"},{"key":"6930_CR15","doi-asserted-by":"publisher","first-page":"21128","DOI":"10.1038\/s41598-023-48190-6","volume":"13","author":"R Tamiya","year":"2023","unstructured":"Tamiya R, Hata M, Tanaka A et al (2023) Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration. Sci Rep 13:21128","journal-title":"Sci Rep"},{"key":"6930_CR16","first-page":"1471","volume":"253","author":"Y Kawashima","year":"2015","unstructured":"Kawashima Y, Oishi A, Tsujikawa A et al (2015) Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Arbeitsphysiologie 253:1471\u20131477","journal-title":"Arbeitsphysiologie"},{"key":"6930_CR17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","volume":"82","author":"M Shirley","year":"2022","unstructured":"Shirley M (2022) Faricimab: first approval. Drugs 82:825\u2013830","journal-title":"Drugs"},{"key":"6930_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729\u2013740","journal-title":"Lancet"},{"key":"6930_CR19","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.ophtha.2011.02.039","volume":"118","author":"DM Brown","year":"2011","unstructured":"Brown DM, Heier JS, Ciulla T et al (2011) Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology 118:1089\u20131097","journal-title":"Ophthalmology"},{"key":"6930_CR20","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10384-021-00869-x","volume":"65","author":"K Yamashiro","year":"2021","unstructured":"Yamashiro K, Oishi A, Hata M et al (2021) Visual acuity outcomes of anti-VEGF treatment for neovascular age-related macular degeneration in clinical trials. Jpn J Ophthalmol 65:741\u2013760","journal-title":"Jpn J Ophthalmol"},{"key":"6930_CR21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10384-023-01040-4","volume":"68","author":"H Matsumoto","year":"2024","unstructured":"Matsumoto H, Hoshino J, Nakamura K, Akiyama H (2024) One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-na\u00efve neovascular age-related macular degeneration. Jpn J Ophthalmol 68:83\u201390","journal-title":"Jpn J Ophthalmol"},{"key":"6930_CR22","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2147\/OPTH.S448507","volume":"18","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Hata M, Tsuchikawa M et al (2024) Short-term outcomes of 3 monthly intravitreal faricimab on different subtypes of neovascular age-related macular degeneration. Clin Ophthalmol 18:507\u2013516","journal-title":"Clin Ophthalmol"},{"key":"6930_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ajo.2008.05.032","volume":"146","author":"RF Spaide","year":"2008","unstructured":"Spaide RF, Koizumi H, Pozzoni MC (2008) Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 146:496\u2013500","journal-title":"Am J Ophthalmol"},{"key":"6930_CR24","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.ajo.2014.02.034","volume":"157","author":"M Adhi","year":"2014","unstructured":"Adhi M, Liu JJ, Qavi AH et al (2014) Choroidal analysis in healthy eyes using swept-source optical coherence tomography compared to spectral domain optical coherence tomography. Am J Ophthalmol 157:1272-1281.e1","journal-title":"Am J Ophthalmol"},{"key":"6930_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10384-023-00985-w","volume":"67","author":"R Mori","year":"2023","unstructured":"Mori R, Honda S, Gomi F et al (2023) Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial. Jpn J Ophthalmol 67:301\u2013310","journal-title":"Jpn J Ophthalmol"},{"key":"6930_CR26","first-page":"2029","volume":"260","author":"I Wada","year":"2022","unstructured":"Wada I, Shiose S, Ishikawa K et al (2022) One-year efficacy of \u201crescue photodynamic therapy\u201d for patients with typical age-related macular degeneration, polypoidal choroidal vasculopathy, and pachychoroid neovasculopathy refractory to anti-vascular endothelial growth factor therapy. Arbeitsphysiologie 260:2029\u20132036","journal-title":"Arbeitsphysiologie"},{"key":"6930_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-024-01146-3","author":"J Hoshino","year":"2025","unstructured":"Hoshino J, Matsumoto H, Nakamura K, Akiyama H (2025) Efficacy of switching to brolucizumab for neovascular age-related macular degeneration refractory to faricimab. Jpn J Ophthalmol. https:\/\/doi.org\/10.1007\/s10384-024-01146-3","journal-title":"Jpn J Ophthalmol"},{"key":"6930_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40942-024-00525-9","volume":"10","author":"FM Penha","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA et al (2024) Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retina Vitreous 10:5","journal-title":"Int J Retina Vitreous"},{"key":"6930_CR29","doi-asserted-by":"publisher","unstructured":"Cheung CMG, Dansingani KK, Koizumi H et al (2024) Pachychoroid disease: review and update. EYE. https:\/\/doi.org\/10.1038\/s41433-024-03253-4","DOI":"10.1038\/s41433-024-03253-4"},{"key":"6930_CR30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00417-021-05445-0","volume":"260","author":"S Inoda","year":"2022","unstructured":"Inoda S, Takahashi H, Inoue Y et al (2022) Cytokine profiles of macular neovascularization in the elderly based on a classification from a pachychoroid\/drusen perspective. Graefes Arch Clin Exp Ophthalmol 260:747\u2013758","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6930_CR31","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1038\/s41598-024-54109-6","volume":"14","author":"KT Nam","year":"2024","unstructured":"Nam KT, Yun C, Seo M et al (2024) Comparison of retinal thickness measurements among four different optical coherence tomography devices. Sci Rep 14:3560","journal-title":"Sci Rep"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06930-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-06930-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-06930-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T03:50:29Z","timestamp":1764820229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-06930-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["6930"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-06930-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Kyoto University Graduate School of Medicine and the Japanese Red Cross Wakayama Medical Center\u00a0and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"According to our institutional review board guidelines, informed consent was not required for the retrospective review of patient medical records.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None of the authors has any proprietary interest in any product described in this article. The authors wish to report the following relationships: M. Hata: Novartis Pharma, Senju Pharmaceutical, Alcon Research Institute, and Kyoto Drug Discovery and Development; A. N. Ueda-Arakawa: Santen Pharmaceutical, Novartis Pharma, and Chugai Pharmaceutical; H. Tamura: Findex, Bayer Yakuhin, Novartis Pharma, Santen Pharmaceutical, SUNTORY, and Otsuka Pharmaceutical; M Miyata: Alcon Japan, Novartis Pharma, Santen Pharmaceutical, HOYA, Bayer Yakuhin, Senju Pharmaceutical, and Kowa Pharmaceutical; A. Tsujikawa: Canon, Findex, Santen Pharmaceutical, Kowa Pharmaceutical, Pfizer, AMO Japan, Senju Pharmaceutical, Wakamoto Pharmaceutical, Alcon Japan, Alcon Pharma, Otsuka Pharmaceutical, Tomey Corporation, Taiho Pharma, Hoya, Bayer Yakuhin, Novartis Pharma, Chugai Pharmaceutical, Astellas, Eisai, Daiich-Sankyo, Janssen Pharmaceutical, Kyoto Drug Discovery and Development, Allergan Japan, MSD, Ellex, HOYA, Sanwa Kagaku Kenkyusho, Nitten Pharmaceutical, and AbbVie GK.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Meeting presentation"}}]}}